Take Homes in Myeloproliferative Neoplasms

In this video, Lindsay A.M. Rein, MD, discussed the Summit trial into treatment of systemic mastocytosis, data from which was presented at the ASH Annual Meeting and Exposition.

In this video, Lindsay A.M. Rein, MD, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Lindsay A.M. Rein, MD, discussed the phase 1/phase 2 TP-3654 study into relapsed/refractory myelofibrosis, data from which she presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the RuxoBEAT study into ruxolitinib treatment in patients with polycythemia vera, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the TRANSFORM-1 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the MANIFEST-2 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Ruben Mesa, MD, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.

In this video, Ruben Mesa, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.